Pair page
Sermorelin with Tesamorelin
Mechanism-tag overlap and published literature for Sermorelin and Tesamorelin, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
ghrh-analog-growth-hormone-secretagogue
fda-approved-ghrh-analogvisceral-adiposity
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Sermorelin and Tesamorelin have published these mechanism-level observations. Not a co-administration recommendation.
Occasionally substituted or rotated with sermorelin. Tesamorelin has a stabilized structure, longer half-life, and more aggressive visceral fat effect. Not typically stacked with sermorelin (same mechanism).
Quick facts
Sermorelin
Tesamorelin
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2012 | Sermorelin | Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-1429.… PMID 22869065 | human study |
| 1999 | Sermorelin | Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157. PMID: 18031173. PMID 18031173 | human study |
| 1996 | Sermorelin | Ghigo E, Aimaretti G, Gianotti L, Bellone J, Arvat E, Camanni F. New approach to the diagnosis of growth hormone deficiency in adults. Eur J Endocrinol. 1996;134(3):352-356. PMID: 8616536. PMID 8616536 | human study |
| 2020 | Sermorelin | Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Commun. 2020;3(1):25-37. | mechanism / discovery |
| 2025 | Sermorelin | WADA. 2025 Prohibited List. Section S2 — Peptide hormones, growth factors, related substances and mimetics. World Anti-Doping Agency. | regulatory / registry |
| 2006 | Sermorelin | Walker RF. Sermorelin: A better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308. PMID: 18046908. PMC2699646. PMID 18046908 | research article |
| 2003 | Sermorelin | Merriam GR, Schwartz RS, Vitiello MV. Growth hormone-releasing hormone and growth hormone secretagogues in normal aging. Endocrine. 2003;22(1):41-48. PMID: 14662999. PMID 14662999 | research article |
| 1997 | Sermorelin | Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in older men and women. J Clin Endocrinol Metab. 1997;82(5):1472-1479. PMID: 9141535. PMID 9141535 | research article |
| 1996 | Sermorelin | Thorner M, Rochiccioli P, Colle M, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab. 1996;81(3):1189-1196. PM… PMID 8772599 | research article |
| 1992 | Sermorelin | Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-535. PMID: 1379256. PMID 1379256 | research article |
| 1992 | Sermorelin | Duck SC, Schwarz HP, Costin G, et al. Subcutaneous growth hormone-releasing hormone therapy in growth hormone-deficient children: first year of therapy. J Clin Endocrinol Metab. 1992;75(4):1115-1120. PMID: 1400880. PMID 1400880 | research article |
| 1985 | Sermorelin | Vance ML, Kaiser DL, Evans WS, et al. Pulsatile growth hormone secretion in normal man during a continuous 24-hour infusion of human growth hormone releasing factor. Evidence for intermittent somatostatin secretion. J Clin Invest. 1985;75(5):1584-1590. PMID: 2860118. PMID 2860118 | research article |
| 2010 | Tesamorelin | Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind place… PMID 20101189 | human trial, Phase 3 |
| — | Tesamorelin | ClinicalTrials.gov. NCT00123253, NCT00435136 (Phase 3 registration); NCT01263717 (JAMA liver fat); NCT02196831 (Lancet HIV NAFLD); NCT00675506 (Arch Neurol cognition). | human trial, Phase 3 |
| 2019 | Tesamorelin | Stanley TL, Fourman LT, Feldpausch MN, Purdy J, Zheng I, Pan CS, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821-e830. PMID: 31611038. PMID 31611038 | human trial |
| 2014 | Tesamorelin | Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. PMID: 25038357. PMID 25038357 | human trial |
| 2005 | Tesamorelin | Falutz J, Allas S, Kotler D, Thompson M, Koutkia P, Albu J, et al. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS. 2005;19(12):1279-1287. PMID: 16052083. PMID 16052083 | human trial |
| 2004 | Tesamorelin | Koutkia P, Canavan B, Breu J, Torriani M, Kissko J, Grinspoon S. Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized, controlled trial. JAMA. 2004;292(2):210-218. PMID: 15249570. PMID 15249570 | human trial |
| 2011 | Tesamorelin | Stanley TL, Falutz J, Mamputu JC, Soulban G, Potvin D, Grinspoon SK. Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction. Clin Infect Dis. 2011;53(11):1150-1158. PMID: 22016502. PMID 22016502 | human study |
| 2008 | Tesamorelin | Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22(14):1719-1728. PMID: 18690162. PMID 18690162 | human study |
| 2007 | Tesamorelin | Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. PMID: 18057338. PMID 18057338 | human study |
| 2011 | Tesamorelin | Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011;71(8):1071-1091. PMID: 21668043. PMID 21668043 | review |
| 2026 | Tesamorelin | World Anti-Doping Agency. The 2026 Prohibited List. Section S2 — Peptide Hormones, Growth Factors, Related Substances and Mimetics. wada-ama.org. | regulatory / registry |
| 2010 | Tesamorelin | U.S. Food and Drug Administration. Egrifta (tesamorelin for injection) Prescribing Information. Initial U.S. Approval: 2010. Latest revision 2024. | regulatory / registry |
Related pair pages
More research context
Frequently asked
Have Sermorelin and Tesamorelin been studied together?
Researchers have published mechanistic-level co-administration discussion of Sermorelin and Tesamorelin. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Sermorelin and Tesamorelin share?
Sermorelin and Tesamorelin do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of Sermorelin and Tesamorelin?
Sermorelin: Approved 1997; discontinued 2008 (commercial). Tesamorelin: Approved (2010). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Sermorelin and Tesamorelin?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Sermorelin profile and the Tesamorelin profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026